Onco-Innovations (CBOE CA: ONCO; Frankfurt: W1H, WKN: A3EKSZ; OTCQB: ONNVF) has announced the appointment of staff radiation oncologist, Dr. Michael Lock, to its scientific and clinical advisory board.
Dr. Lock is a professor in the department of oncology and the department of medical biophysics at the University of Western Ontario. According to Onco, his expertise in clinical trial design, translational oncology, and multidisciplinary cancer care will support the company in its development of novel therapies, including its PNKP inhibitor program.
In a statement, Thomas O’Shaughnessy, CEO of Onco, commented, “Dr. Lock’s deep clinical trial expertise and proven leadership in integrating research with patient care make him an invaluable addition to our team. His perspective will be critical as Onco advances toward clinical development of our PNKP inhibitor program and other research initiatives, particularly in shaping trial strategy and execution.”
